Core Viewpoint - BeiGene (ONC.US) reported strong financial results for Q3, with revenue exceeding 10 billion RMB, leading to an upward revision of its 2025 revenue guidance [1] Financial Performance - In Q3, BeiGene's revenue reached 10.077 billion RMB, a year-on-year increase of 41.1% [1] - Product revenue was 9.954 billion RMB, growing by 40.6% year-on-year [1] - For the first three quarters of 2025, revenue totaled 27.595 billion RMB, up 44.2% compared to the previous year [1] - The company's product revenue for the same period was 27.314 billion RMB, reflecting a 43.9% increase year-on-year [1] - Net profit attributable to shareholders reached 1.139 billion RMB, driven by significant product revenue growth and improved operational efficiency [1] Guidance and Market Position - BeiGene revised its 2025 full-year revenue guidance to a range of 36.2 billion to 38.1 billion RMB, up from the previous estimate of 35.8 billion to 38.1 billion RMB [1] - The revenue growth is primarily attributed to the leading position of Brukinsa (Zebutinib) in the U.S. market and its ongoing expansion in Europe and other key global markets [1] Cost Management - Research and development expenses, along with sales and management costs, are expected to narrow to a range of 29.5 billion to 30.9 billion RMB, reflecting prudent investment strategies that enhance revenue and pipeline growth [1]